This podcast was developed and funded by LEO Pharma and is intended only for healthcare professionals.
Please note that this podcast was developed in accordance with the betamethasone dipropionate, calcipotriol monohydrate SmPCs.
Click here for the UK Enstilar (betamethasone diproprionate, calcipotriol monohydrate) SmPC.
Enstilar is indicated for the topical treatment of psoriasis vulgaris in adults.
Please be aware that the label within your country may differ due to local regulations, and you should always consult your own label for prescribing and safety information about Enstilar.
Topics Covered:
- How topical vehicle design can influence drug delivery, efficacy, tolerability, and patient experience
- Key principles of penetration, permeation, and absorption, and how formulation characteristics can affect drug delivery
- How formulation approaches, including penetration enhancers and barrier-conscious design, can influence treatment outcomes in inflammatory skin disease
Speaker
Leon Kircik 1-5
- Icahn School of Medicine at Mount Sinai, New York, USA
- Indiana University Medical Center, Indianapolis, USA
- Physicians Skin Care, PLLC, Louisville, Kentucky, USA
- DermResearch, PLLC, Louisville, Kentucky, USA
- Skin Sciences, PLLC, Louisville, Kentucky, USA
Kircik has received funding from LEO Pharma and is a paid consultant for LEO Pharma.
| Adverse events should be reported. For the United Kingdom, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App Store. Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0) 1844347333 or e-mail [email protected]. |
MAT-100193 | Date of Preparation: November 2026
